2019 Postgraduate Course: Precision Hepatology in Clinical Practice

4.93 (15 votes)

Recorded On: 11/09/2019

DESCRIPTION
The practice of Hepatology is largely consultative in nature, whether evaluating outpatients referred for a variety of abnormal liver enzyme findings or diagnosing and managing critically-ill patients within a team of internists, hospitalists, residents, intensivists, and other healthcare providers. On any given day, a hepatologist will be confronted with complex patients and dizzying differential diagnoses to be methodically considered. The aim of this course is to provide insights about state-of-the-art consultative Hepatology attendees that can be applied to daily practice.

CREDITS OFFERED
Continuing Medical Education (CME): For a maximum of 7.00 AMA PRA Category 1 Credits™  
Maintenance of Certification (MOC): For a maximum of 7.00 MOC Points

COMPONENTS
Online presentations comprised of PowerPoint slides and accompanying audio with an assessment to complete at the end. 
-Five sessions comprised of three to five video presentations for 15-20 minutes each
-Course assessment (quiz)
-Course evaluation to claim continuing education credit

DIRECTIONS
Click "Activate/Register" to access the enduring material. Review all section tabs before you begin. Begin video presentations in all sessions. Complete course assessment and evaluation to claim CME and or MOC.
Time to complete each module: 15-20 minutes

COPYRIGHT
All faculty in this activity have given their permission for publication ©2020 AASLD. 

CONTACT INFORMATION
For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org.

Release date: January 9, 2020
Expiration date: January 8, 2023

Upon completion of this activity, participants will be able to:

Review evidence-based evaluation and management options available for a spectrum of liver diseases, their benefits and risks, and strategies to tailor treatment plans to individual patients.

Discuss the value of circulating and tissue biomarkers in making rational decisions for optimal patient care.

Apply information on minimally invasive tests and digital tools to identify biomarkers to the clinical practice of hepatology.

Hepatologists   

Gastroenterologists       

Nurses

Nurse Practitioners        

Pharmacists

Physician Assistants       

Transplant Coordinators

Surgeons            

Fellows/Trainees

CREDITS OFFERED
Continuing Medical Education (CME): For a maximum of 7.00 AMA PRA Category 1 Credits™
Maintenance of Certification (MOC): For a maximum of 7.00 MOC Points

ACCREDITATION AND DESIGNATION STATEMENTS 
Continuing Medical Education (CME) The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 7 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

HOW TO EARN AND CLAIM MOC POINTS 

             o    View all video presentation in each session.

             o    Complete the course evaluation.

             o    Complete the CME and MOC assessment. You must pass with a score of 70% or higher. Participants have unlimited attempts to earn the passing score.

             o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

MOC completions are collected on the 15th of each month and submitted to ABIM and ABP by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM or ABP MOC profile.

**MOC points are available for ABIM or ABP board certified physicians only.**

Robert Fontana, MD, FAASLD

Kathryn Fowler, MD

Scott Friedman, MD, FAASLD

Fasiha Kanwal, MD, MSHS, FAASLD

Tom H. Karlsen, MD, PhD

Verena Keitel, Prof.

Laura Kulik, MD

Jennifer C. Lai, MD

Konstantinos Lazaridis, MD, FAASLD

Joseph Llovet, MD

Michael Lucey, MD, FAASLD

Cara Mack, MD, FAASLD

Alexander Miethke, MD

Tushar Patel, MBCHb, FAASLD

Mary Rinella, MD, FAASLD

Don Rockey, MD, FAASLD

Bernd Schnabl, MD, FAASLD

Gyongyi Szabo, MD, PhD, FAASLD

Norah Terrault, MD, MPH, FAASLD

Michael Trauner, MD, FAASLD

Kymberly Watt, MD

DISCLOSURE OF CONFLICTS OF INTEREST
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

This enduring activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the AASLD Postgraduate Course faculty and the following planning committees: Education Committee, Scientific Program Committee and the Governing Board.

As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months.  A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  All conflicts of interest are resolved prior to participation.

Statement on off-label and investigational use: Speakers are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device. Financial disclosures will appear at the beginning of each session and are provided below:

FACULTY DISCLOSURES

Meena Bansal
AASLD Postgraduate Course Faculty
Nothing to Disclose

Ulrich Beuers
AASLD Postgraduate Course Faculty
Grant/Research Support: Intercept, Dr.Falk GmbH
Speaking and Teaching: Intercept, Falk Foundation

Jorge Bezerra
AASLD Postgraduate Course Faculty
Nothing to Disclose

Raymond Chung
AASLD Postgraduate Course Faculty
Advisory Committee or Review Panel: Alnylam
Grant/Research Support: Boehringer, BMS, Merck, Gilead, Abbvie, Janssen, Roche, Synlogic, Kaleido

Robert Fontana
AASLD Postgraduate Course Faculty
Consulting: Sanofi
Grant/Research Support: BMS, Gilead, Abbvie

Kathryn Fowler
AASLD Postgraduate Course Faculty
Consulting: 12 Sigma

Scott Friedman
AASLD Postgraduate Course Faculty
Consulting: 3BV Bio, 89Bio, Abide Thearapeutics, Allergan Pharmaceuticals, Avaliv Therapeutics, Axcella Therapeutics, Blade Therapeutics, Bristol Myers Squibb, Contravir, CymaBay, DeuteRx, Enanta Pharmaceuticals, Escient Therapeutics, Exalenz Biosciences, Forbion, Fractyl Bioscience, Five Prime Therapeutics , Galmed, Genfit, Gemphire, Glycotest, Heparegenix, Janssen Pharmaceuticals, Jecure Therapeutics, Kintai, Madrigal Pharmaceuticals, Metacrine, Mistral, Morphic Rock Therapeutics, NGM Pharmaceuticals, Nimbus Therapeutics, Nitto Corp., North Sea Therapeutics, Novartis, Novo Nordisk, Pfizer Pharmaceuticals, Salix, Scholar Rock, Seal Rock Therapeutics, Second Genome, Surrozen, Symbic Bio, Takeda Pharmaceuticals, Viking Therapeutics
Grant/Research Support: 3VBio, Enanta, Scholar Rock, Gemphire, North Sea Therapeutics

Fasiha Kanwal
AASLD Postgraduate Course Faculty
Grant/Research Support: Merck, Gilead

Tom Karlsen
AASLD Postgraduate Course Faculty
Nothing to Disclose

Andrew Keaveny
AASLD Postgraduate Course Faculty
Grant/Research Support: HepQuant LLC, Conatus Pharmaceuticals, Mallinckrodt Medical Inc
Independent Contractor: UpToDate Inc
Speaking and Teaching: Medscape Inc.

Verena Keitel
AASLD Postgraduate Course Faculty
Speaking and Teaching: Abbvie, Falk Foundation

Laura Kulik
AASLD Postgraduate Course Faculty
Nothing to Disclose 

Jennifer C. Lai
AASLD Postgraduate Course Faculty
Consulting: Axcella Health, Inc

Konstantinos Lazaridis
AASLD Postgraduate Course Faculty
Nothing to Disclose

Josep Llovet
AASLD Postgraduate Course Faculty
Consulting: Ipsen, Merck, Bristol Myers Squibb, Eisai Inc, Bayer HealthCare Pharmaceuticals, Midatech Ltd, Navigant, Fortress Biotech Inc, Spring Bank Pharmaceutical, Glycotest, Leerink Swann LLC, Eli Lilly, Celsion Corporation, Exelixis, Nucleix, Can-Fite Biopharma
Grant/Research Support: Bristol Myers Squibb, Eisai Inc, Bayer Healthcare Pharmaceuticals, Ipsen, Blueprint Incyte

Rohit Loomba
AASLD Postgraduate Course Faculty
Consulting: Bird Rock Bio, Merck & Co., NGM, Cymabay, Metacrine, Ionis, Glympse Bio, Pfizer, Eli Lilly and Company
Grant/Research Support: Intercept, NGM Bio, Novo Nordisk, Novartis, Prometheus, Janssen, Cirius Therapeutics, Gilead, Eli Lilly

Michael Lucey
AASLD Postgraduate Course Faculty
Grant/Research Support: NIAAA, Pharma-solutions, Gilead, Abbvie

Cara Mack
AASLD Postgraduate Course Faculty
Consulting: albireo

Alexander Miethke
AASLD Postgraduate Course Faculty
Consulting: Mirum Inc, Metacrine Inc
Lopa Mishra
Research Grants: NIH

Vicky Ng
AASLD Postgraduate Course Faculty
Advisory Committee or Review Panel: Albireo

Tushar Patel
AASLD Postgraduate Course Faculty
Disclosures were not provided

Nancy Reau
AASLD Postgraduate Course Faculty
Advisory Committee or Review Panel: Gilead, intercept, Merck, abbVie
Consulting: BMS
Grant/Research Support: GenFit

Mary Rinella
AASLD Postgraduate Course Faculty
Consulting: NGM Biopharmaceuticals, Genfit, Gilead, Intercept, Novartis, Metacrine, Bristol Meyers Squibb, Gelesis, Fractyl, Pfizer, Madrigal, Enanta, Echosens, Merck, Viking
Grant/Research Support: Gilead, Conatus, NGM, Cirius, Enanta, Intercept, Novartis, Allergan

Don Rockey
AASLD Postgraduate Course Faculty
Grant/Research Support: Terlipressin, Intercept Pharm, Mallinckrodt Pharm, Genfit Reg, INC, Aflmmune, Salix, Cumberland Pharm, NIH/NIDDK, Ironwood Pharm, Gilead Services, Conatus Pharm

Bernd Schnabl
AASLD Postgraduate Course Faculty
Consulting: Ferring Pharmaceuticals, Patara Pharmaceuticals, Intercept Pharmaceuticals
Grant/Research Support: CymaBay Therapeutics, Synlogic Operating Company

Ronald Sokol
AASLD Postgraduate Course Faculty
Consulting: Alexion, Retrophin, Shire, Albireo

Gyongyi Szabo
AASLD Postgraduate Course Faculty
Advisory Committee or Review Panel: UPENN Digestive Disease Center, Yale Liver Center, BWH-DSMB, VCU MSTP, NIH ExRNA Program, UCLA Liver Center, Galaxy Project, Nature Gastro & Hepatology, University of Pittsburgh MSTP Program, University of Louisville Alcohol Center, Upstate Medical Univ. Syracuse NY, Carlos Foundation- Mayo Clinic, MICA

Norah Terrault
AASLD Postgraduate Course Faculty
Grant/Research Support: Gilead Sciences

Michael Trauner
AASLD Postgraduate Course Faculty
Consulting: Albireo, BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Intercept, MSD, Novartis, Phenex, Regulus
Grant/Research Support: Albireo, Cymabay, Falk, Gilead, Intercept, MSD, Takeda
Speaking and Teaching: Falk, Gilead, Intercept, MSD, Roche

Kymberly Watt
AASLD Postgraduate Course Faculty
Stock Shareholder: Arbutus, Madrigal, Viking, BMS

Rebecca Wells
AASLD Postgraduate Course Faculty
Nothing to Disclose

PLANNER DISCLOSURES

Veeral Ajmera 
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Luminist Incorporated

Gyorgy Baffy 
Annual Meeting Education Committee
Nothing to Disclose 

Meena Bansal
Governing Board and Scientific Program Committee
Data Safety Monitoring Board for Industry or Commercial Enterprise: TREAT Consortium (NIH; not commercial entity)                                                                                                                                           
Research Grants: Paid to institution:  NIH R01                                                                                                         
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Kinetix Group; Boehringer-Ingelheim 

Ramon Bataller
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Echosens

Alex Befeler 
Scientific Program Committee
Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: Amgen
long term stockholder (independently managed by CPA), Gilead long term stockholder (independently managed by CPA)                                                                                                                                       
Research Grants: mallinckrodt, Salix, Sillajen 

Jorge Bezerra 
Governing Board and Scientific Program Committee
Research Grants: Gilead; Shyer

Andres Cardenas 
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Boston Scientific Corp Scientific                                                                   
Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Mallinckrodt Pharmaceuticals - Consultant

Raymond Chung 
Governing Board and Scientific Program Committee
Data Safety Monitoring Board for Industry or Commercial Enterprise: DSMB Alnylam                     
Research Grants: Gilead Sciences. Abbvie, Boehringer Ingelheim, BMS, Roche, Janssen, Merck, Kaleido, Synlogic

Virginia Clark 
Annual Meeting Education Committee
Research Grants: Genfit

James Daniel 
Annual Meeting Education Committee
Research Grants: Gilead and Hoffmann- La Roche

Laurie DeLeve 
Annual Meeting Education Committee and Governing Board
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Abbvie, Pfizer, Daiichi Sankyo, Boehringer-Ingelheim                                                     
Intellectual Property Rights (Patents, Royalties, Licensing fees): 2017-230-01 US no. 62/544,589 End-organ selective MMP inhibition enhances bone marrow progenitor cell recruitment, COMPOSITIONS AND METHODS FOR AMELIORATING TISSUE INJURY, ENHANCING LIVER REGENERATION AND STEM CELL THERAPIES -(sole inventor) - Applicant: University of Southern California, GBC ref.: 6177.132445PCT

Michael Fried 
Governing Board and Scientific Program Committee
Research Grants: AbbVie, BMS, Gilead, Merck, National Institutes of Health
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated)                                        Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: TARGET PharmaSolutions (Maintained in independent blind trust)

Patrick Horne 
Annual Meeting Education Committee and Scientific Program Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Abbvie, Gilead, Intercept

Sofia Jakab 
Annual Meeting Education Committee
Nothing to Disclose 

Michael Kriss 
Annual Meeting Education Committee
Nothing to Disclose

Laura Kulik
Annual Meeting Education Committee
Nothing to Disclose 

John Lake 
Governing Board
Research Grants: CymbaBay, Data Safety                                                                                                           
Monitoring Board for Industry or Commercial Enterprise: Intercept DSMB                                             
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: SRTR

Bruce Luxon 
Governing Board
Data Safety Monitoring Board for Industry or Commercial Enterprise: DSMB for Baxalta; DSMB for Sparks (for treatment of Hemophilia)                                                                                                               
Leadership in related society: Board, Committee, Journal: Research Committee member for the ACG

John Magee
Scientific Program Committee
Nothing to Disclose

Mitchell Mah'moud 
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Chronic Liver a Disease Foundation

Harmeet Malhi
Scientific Program Committee
Research Grants: NIH R01 NIH U01

Lopa Mishra 
Governing Board
Research Grants: NIH

David Mulligan 
Governing Board
Nothing to Disclose

Mary Panther  
Annual Meeting Education Committee
Nothing to Disclose 

K. Gautham Reddy 
Scientific Program Committee
Research Grants: CymaBay; Genfit; Intercept; Target PharmaSolutions; Arrowhead; Gilead; Durect;
Commercial Speaker's Bureau: Intercept, Dova                                                                                           
Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept

Hemant Shah 
Annual Meeting Education Committee
Advisory Board: Abbvie, Gilead, Intercept, Lupin, Merck, Pendopharm

Ronald Sokol 
Governing Board
Research Grants: Paid to institution: Lumena/Shire; Albireo
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Alexion; Albireo; Retrophin; Shire; Mirum

Richard Sterling  
Annual Meeting Education Committee
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Gilead, Roche, AbbVie, Baxter, Pfizer, Merck within the last 12 months.  
I have had no activity with Gilead, AbbVie, and Merck in the last 6 months in anticipation of the Non-Invasive Guidelines paper that is expected to start 2018.
Research Grants: Gilead, Roche, True Health, AbbVie, Abbott

Grace Su 
Annual Meeting Education Committee and Scientific Program Committee
Intellectual Property Rights (Patents, Royalties, Licensing fees): Patent on Image analysis and Morphomic
Leadership in related society: Board, Committee  Journal: Member, Clinical Guidelines Committee, AGA; Company Employee, Officer, Director : My husband and son have equity interest in Applied Morphomics and Prenovo.

Norah Terrault
Governing Board
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Advisory Committees or Review Panels: Dova Pharmaceuticals       
Research Grants: Grant/Research Support: AbbVie, Gilead, BMS, Merck 

Jason Vanatta 
Annual Meeting Education Committee
Nothing to Disclose 

Kymberly Watt
Scientific Program Committee                                                                                               
Expert testimony: Intercept - site- PI
Gilead - site PI, co-I
Conatus - site co-I
Novartis - previous site PI, co author study subanalysis
Pfizer- site co-I (all multicenter study related)                                                                                                   
Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: BMS; Arbutus; Madrigal; Viking

Steven Weinman 
Annual Meeting Education Committee
Nothing to Disclose

Maureen Whitsett 
Annual Meeting Education Committee
Nothing to Disclose 

AASLD STAFF DISCLOSURES

Greg Bologna 
AASLD Staff 
Nothing to Disclose

Dominique Clayton
AASLD Staff
Nothing to Disclose

Amy D'Amato 
AASLD Staff
Nothing to Disclose

Julie Deal 
AASLD Staff 
Nothing to Disclose

Katie Duggan
AASLD Staff
Nothing to Disclose

Stephanie Graham
AASLD Staff 
Nothing to Disclose

Stephanie Grimsby 
AASLD Staff
Nothing to Disclose

Jessica Jessop
AASLD Staff 
Nothing to Disclose

Janeil C. Klett 
AASLD Staff 
Nothing to Disclose

John Lingerfelt
AASLD Staff 
Nothing to Disclose

Julia Merrill
AASLD Staff 
Nothing to Disclose

Bette Anne Preston
AASLD Staff 
Nothing to Disclose

Diane Perrino 
AASLD Staff
Nothing to disclose

Denise Seise
AASLD Staff
Nothing to disclose

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.

Key:

Complete
Failed
Available
Locked
Precision Hepatology in Clinical Practice Introduction to Course
Open to view video.
Open to view video.
Session I: Precision Medicine in 2019
The Spectrum of Precision Medicine
Open to view video.
Open to view video. Presenter: Konstantinos Lazaridis
Influence of the Microbiome on Liver Disease Phenotype and Outcome
Open to view video.
Open to view video. Presenter: Bernd Schnabl
Precision Medicine and Patients at Risk for Drug-induced Liver Injury*
Open to view video.
Open to view video. Presenter: Robert Fontana
Clinical Models and Risk Assessment: Acute-on-Chronic Liver Failure as a Paradigm
Open to view video.
Open to view video. Presenter: Jennifer C. Lai
Session II: Evolution of Disease and Reversing Fibrosis
Non-alcoholic Fatty Liver Disease: Non-invasive Phenotyping
Open to view video.
Open to view video. Presenter: Mary Rinella
Phenotyping NAFLD: Risk Stratification and Managing Co-Morbidities*
Open to view video.
Open to view video. Presenter: Kymberly Watt
Reversing Liver Fibrosis: Predicting and Monitoring Structural Changes*
Open to view video.
Open to view video. Presenter: Don Rockey
Session III: Autoimmune Diseases and Cholestasis
Precision Therapy in Patients with Primary Biliary Cholangitis*
Open to view video.
Open to view video. Presenter: Michael Trauner
Predictors of Disease Progression and Complications of Primary Sclerosing Cholangitis
Open to view video.
Open to view video. Presenter: Tom H. Karlsen
Autoimmune Liver Disease in Younger Patient: Crossing Phenotypic Boundaries*
Open to view video.
Open to view video. Presenter: Alexander Miethke
Biliary Atresia: Biomarkers of Disease and Predictors of Outcome*
Open to view video.
Open to view video. Presenter: Cara Mack
Session IV: Hepatic Neoplasms
Managing HCV Cirrhotic Patients After Achieving SVR: Who Will Progress to Developing Hepatocellular Carcinoma?*
Open to view video.
Open to view video. Presenter: Tushar Patel
Non-invasive Assessment of Small Liver Lesions
Open to view video.
Open to view video. Presenter: Kathryn Fowler
Precision Medicine to Guide Therapy in Liver Cancer
Open to view video.
Open to view video. Presenter: Joseph Llovet
Emerging Treatment Options for HCC and Cholangiocarcinoma*
Open to view video.
Open to view video. Presenter: Laura Kulik
Session V: Questions, Controversies and Value of Care
Genetic Testing in Adults with Liver Disease: Improving Diagnostic Algorithms
Open to view video.
Open to view video. Presenter: Verena Keitel
Precision Treatment of HBV: Envisioning Curative Therapies*
Open to view video.
Open to view video. Presenter: Norah Terrault
Personalizing Longitudinal Care of Patients with Cirrhosis
Open to view video.
Open to view video. Presenter: Fasiha Kanwal
Case-based Debate: Balancing the Costs and Benefits of Individualized Medicine*
Open to view video.
Open to view video. Moderator: Scott Friedman Panelist: Michael Lucey
Case-based Debate: Balancing the Costs and Benefits of Individualized Medicine*
Open to view video.
Open to view video. Moderator: Scott Friedman Panelist: Gyongyi Szabo
From Discovery Science to Clinical Care: Where Do We Want to Go?
Open to view video.
Open to view video. Presenter: Scott Friedman
Credits, Certificates & Evaluations- Online Course
2019 Postgraduate Course: Precision Hepatology in Clinical Practice Evaluation
7 Questions
7 Questions Please complete the following evaluation form to share your feedback on this activity.
Quiz
17 Questions  |  Unlimited attempts  |  12/17 points to pass
17 Questions  |  Unlimited attempts  |  12/17 points to pass
CME Credits
Up to 7.00 medical credits available  |  Certificate available
Up to 7.00 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
ABIM/ABP # and Date of Birth needed to claim MOC successfully.
ABIM/ABP # and Date of Birth needed to claim MOC successfully.
MOC Points
Up to 7.00 medical credits available  |  Certificate available
Up to 7.00 medical credits available  |  Certificate available